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Summary
Cancer is a major public health issue worldwide. It is very important to have high-quality epidemiological data to plan 
the measures in primary, secondary and tertiary prevention, to benchmark in comparison to other countries and to assess 
trends for particular cancer sites. This paper presents the basic epidemiology indicators for Croatia, explains the concepts 
surrounding the data collection and analytical procedures for essential epidemiological parameters and presents the most 
recent data, estimates and comparisons in the advent of the first Croatian National Cancer Plan.
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EPIDEMIOLOGIJA RAKA U HRVATSKOJ – NEDAVNI UVIDI I MEĐUNARODNE USPOREDBE
Sažetak
Rak je veliki javnozdravstveni problem na cijelom svijetu. Iznimno je važno imati kvalitetne epidemiološke podatke 
kako bismo mogli planirati mjere primarne, sekundarne i tercijarne prevencije, usporediti se s drugim državama i procijeni-
ti trendove za pojedina sijela raka. Ovaj članak opisuje osnovne epidemiološke indikatore za Hrvatsku, razjašnjava načine 
prikupljanja podataka i analitičkih procedura za te indikatore te iznosi najnovije podatke, procjene i usporedbe u osvit pr-
vog hrvatskog Nacionalnog plana za borbu protiv raka. 
KLJUČNE RIJEČI: Hrvatska, registar za rak, incidencija, mortalitet, preživljenje, GLOBOCAN, ECIS
INTRODUCTION
Cancer has become an extremely important 
public health problem for modern society with its 
importance at population level increasing due to 
the improvements in life expectancy. It is often re-
ferred to as a single disease, however it is an ex-
tremely heterogeneous group of diseases that be-
gin with a malignant change of one cell of an or-
ganism that further uncontrollably divides (1). 
The reasons for this change may be different for 
different types of cancer (risk factors) and it is im-
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portant to understand which ones are associated 
with which cancer type in order to know which 
populations are at higher risk (2).
Majority of this information is based on the 
results of scientific studies and population-based 
data (e.g. connection between smoking and lung 
cancer) (3). Over time, with improvement of the 
health status in developing countries and changes 
in the prevalence of possible risk factors, it became 
increasingly important to have a systematic in-
sight in cancer burden on a national or regional 
level. The first regional cancer registries were es-
tablished before World War II and became signifi-
cant in the second half of the 20th century (4).
As a basic dataset, cancer registries collect 
data on cancer patients, type of cancer (site, type, 
stage) and vital status of the person (alive/dead) 
(5) in order to calculate three of the four basic epi-
demiological parameters to estimate the burden of 
cancer: incidence, representing a number of new 
cases in one year; prevalence (number of people 
currently alive that were diagnosed with cancer) 
and survival (usually 5-year survival, the percent-
age of people still alive five years after being diag-
nosed with cancer). The fourth basic parameter, 
cancer mortality (number of deaths due to cancer 
in one year) is based on coroner’s assessment of 
the underlying cause of death, which is then used 
as an additional source of data. Taking into ac-
count the methods of collecting and controlling of 
data quality, most of the cancer registries publish 
their annual reports one and a half to two years 
after the end of calendar year to which the data 
relate (6).
Regions or countries are usually compared by 
two basic criteria, incidence (number of new cases 
per 100 000 population) and mortality (number of 
deaths per 100 000 population), because it is easier 
to collect reliable data for those two than for sur-
vival and prevalence. These indicators can show us 
the main priorities in a country, how it fares in 
comparison to other countries, and are there some 
favourable or unfavourable trends. The so-called 
age-standardized rate is used when comparing 
countries with cancer incidence rates or cancer 
mortality rates (or disease trends over certain peri-
od). This age-standardized rate (can be calculated 
using different standard populations) controls for 
differences between populations in their age struc-
ture and removes possible confounding by age (7). 
These differences must always be taken into ac-
count when making comparisons or assessing 
trends, e.g., there are many more newly cancer pa-
tients today and the overall (crude) incidence rate 
of cancer in Croatia now is much higher than 50 
years ago (8), but there are also far more elderly 
people (both in absolute and relative terms) living 
in Croatia today than in 1969.
WORLDWIDE ESTIMATES
International Agency for Research on Cancer 
(IARC) is responsible for several key projects like 
GLOBOCAN (https://gco.iarc.fr/), Cancer Inci-
dence in Five Continents (http://ci5.iarc.fr/Default.
aspx), International Incidence of Childhood Cancer 
(https://iicc.iarc.fr/), and many others. The Global 
Cancer Observatory is a platform where the latest 
global estimates for 2018 can be found, along with 
actual cancer registries’ data for up to 2012 and 
trends over time (9-11). This data can further be 
analysed and presented using a variety of analyti-
cal and visual options, providing us with some an-
swers in the understanding of cancer epidemiolo-
gy, and indicating possible etiologic causes.
For example, the most common diagnoses of 
cancer (incidence) by country in women (Figure 1) 
are influenced by various factors. These can be 
due to genetic factors, behavioural and environ-
mental risk factors and the availability of diagnos-
tic procedures; we can see that breast cancer is the 
most commonly diagnosed cancer in women in 
85% countries in the world.
The most important causes of cancer mortal-
ity in women by country (Figure 2) indicate a dif-
ferent situation, influenced of course by prognosis 
for each particular cancer type, with breast cancer 
being the leading cause of death for 56% of the 
countries worldwide, and a significant number 
countries having lung or cervical cancer as the 
main cancer cause of death in women. 
EUROPEAN ESTIMATES
Detailed data and estimates across European 
countries can be found at ECIS (European Cancer 
Information System; https://ecis.jrc.ec.europa.eu/). 
This website provides not only incidence and 
mortality estimates (developed in collaboration 
with IARC), but also survival rates from a major 
EUROCARE study on survival of cancer patients 
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Figure 1. The most common cancer by incidence in world, 2018, females (11)
Figure 2. The most common cancer by mortality rates in world, 2018, females (11)
in Europe (12). Taking into account European esti-
mates of cancer incidence and mortality in 2018, 
using the new European Standard Population 
(Figures 3 and 4), Croatia is a country with a me-
dium to high cancer incidence rates and high mor-
tality rates. 
CROATIAN NATIONAL CANCER REGISTRY
The Croatian National Cancer Registry has 
started collecting data in 1959, making it one of 
the oldest registries in Europe and worldwide. 
The first report was published in 1968 (14). There 
are four basic data sources: notifications from pri-
mary health care providers (family medicine prac-
titioners) and tertiary care providers (hospitals), 
copies of histopathological findings confirming 
cancer diagnosis, and information on causes of 
death in Croatia. Patient discharge diagnosis is a 
supplementary data source, which are then used 
for case finding procedures to complement the da-
tabase and improve data coverage and quality.
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According to the latest official data from the 
Croatian National Cancer Registry for 2016, 23,650 
new cases of malignancies (12,632 in men and 
11,018 in women) were confirmed, crude inci-
dence rate was 566,6/100,000 (626,9/100,000 for 
men and 510,2/100,000 for women) (15). Findings 
are related to C00-C96 diagnoses, classified by In-
ternational Classification of Diseases, 10th Edition, 
excluding non-melanoma skin cancers (C44).
Latest records for Croatia, in 2018, found that 
the total number of deaths from invasive cancer 
(without non-melanoma skin cancers) was 13,809 
(crude mortality rate 337,8/100,000), of which 
8,049 were men (mortality rate 407,5/100,000) and 
5,849 women (mortality rate 272,6/100,000) (16).
The most common causes of death in 2018 in 
Croatian men were lung cancer (2,097 deaths), 
colorectal cancer (1,321) and prostate cancer (772), 
while in women the most common ones were 
colorectal cancer (919), lung cancer (860) and breast 
cancer (789) (16).
Using cancer registry data, the regional dis-
tribution of cancer cases can also be assessed, vi-
sualising the current situation, highlighting differ-
ences in the regional cancer burden and support-
ing further research into possible reasons for these 
differences. 
TRENDS
Perhaps the most important information that 
can be elucidated from the cancer registry data are 
trends for each cancer type. These trends are ex-
tremely important for measuring the changes in 
cancer burden that come along with changes in 
the environmental and behavioural risk factors, as 
well as changes in the availability of diagnostic 
and therapeutic modalities, including screening 
programmes.
For instance, with a time delay, lung cancer 
trends will follow up changes in the prevalence of 
smoking in the population, since smoking is con-
sidered as cause of about 85% of all lung cancer 
cases. Although lung cancer is still far more com-
mon in men than in women, incidence and mor-
tality trends are completely opposite (Figures 5 
and 6); in men, the age-standardized incidence 
rate per 100,000 population declines with an an-
nual percentage change (APC) of -1.4% (95% CI 
-1.8 to -1.0) and mortality declines with APC of 
Figure 3. Cancer incidence rates in Europe in 2018, European 
Cancer Information System (13)
Figure 4. Cancer mortality rates in Europe in 2018, European 
Cancer Information System (13)
Figure 5. Trends in age-standardised incidence for lung cancer 
in Croatia, by sex, 2001-2016
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-1.1% (95% CI -1.2 to -0.9). In women, incidence 
rates increase with an APC of +2.3% (95% CI 1.4 to 
3.2) and mortality rates with an APC of +2.7% 
(95% CI 2.3 to 3.1); all p values less than 0.001. 
CANCER SURVIVAL
Prognosis after a diagnosis of a certain dis-
ease is a major factor for anyone included in health 
care system. Besides cancer incidence and cancer 
mortality, it is necessary to ascertain survival rates 
for each type of cancer and compare those results 
with other countries, as a benchmarking tool. The 
CONCORD-3 study, published in 2018 (17), anal-
ysed medical data from 322 cancer registries in 71 
countries in order to compare 5-year net survival 
in more than 37.5 million patients (adult and chil-
dren) diagnosed with one of the 18 most common 
cancer types, in the period from 2000 to 2014.
The Croatian National Cancer Registry also 
took part in this study. Data for more than 220,000 
patients were included and compared to data col-
lected from countries all over the world. The sur-
vival rates from Croatia and other participating 
European countries are presented here for the last 
5-year period (2010-2014).
It is important to emphasize that for almost 
all types of cancer, cancer survival in Croatia is 
improving (Figure 7). However, when observing 
trends and data from earlier years, other compa-
rable countries are often improving faster so there 
is plenty of room for further progress. 
PREVALENCE
Prevalence (number of all people alive at some 
point and found to be affected by specific disease/
condition) has been rarely used basic parameter in 
cancer epidemiology for many reasons. However, 
due to improvements in prognosis for many ma-
lignancies and longer life expectancy, it is becom-
Figure 6. Trends in age-standardised mortality rates for lung 
cancer in Croatia, by sex, 2001-2018
Figure 7. Survival trends in Croatia for selected cancer sites, 2000-2014, according to CONCORD-3 study (17)
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ing more important to know what proportion of 
population has been affected by cancer during 
their lifetime, even if the diagnosis has been made 
more than five years ago. Considering human mi-
gration in Croatia over the last 30 years, the exact 
cancer prevalence is difficult to ascertain. Prelimi-
nary estimates based on cancer registry data indi-
cate that around 170,000 people living in Croatia 
have been diagnosed with a malignant disease at 
some point in their lives, equalling around 4% of 
the total population (data not yet published). 
About 65,000 of those cases were diagnosed in the 
last 5 years, based on the estimates from the GLO-
BOCAN 2018.
RISK FACTORS AND LEVELS  
OF PREVENTION
Data on the health-related habits of Croatian 
population are also worrying; according to the 
percentage of smokers, the percentage of obese 
people and those not adhering to recommended 
nutrition we are far worse than the EU average, 
which of course has a significant impact on the 
higher incidence of cancer (18). At the primary 
level, activities are needed to promote healthy life-
styles and prevention of harmful living habits, 
with the participation of the Croatian Institute of 
Public Health and the network of county public 
health institutes through various programs, coor-
dinated by the Ministry of Health.
Three national cancer screening programs 
have been launched in Croatia, coordinated by the 
Croatian Institute of Public Health: breast, colon 
and cervical cancer, which are, at the population 
level, considered as the most effective secondary 
prevention measure (19-21). The program for in-
troduction of lung cancer screening is currently in 
its preparation phase, expecting the start of the 
program in 2020 (22).
Tertiary prevention is carried out by ensuring 
that the required therapeutic modalities are avail-
able to those who are needed. Western countries’ 
experiences show that it is of utmost importance to 
have a clear strategy on how to improve the epide-
miological situation. This is achieved through the 
adoption of a National Cancer Plan, and it is con-
sidered that the adoption of the National Cancer 
Control Plan will bring additional improvements to 
the comprehensive monitoring, prevention and 
treatment of cancer with integrated tertiary preven-
tion measures and optimization of health care for 
oncological patients (23). Work on the first Croatian 
Cancer Plan has been ongoing, under the coordina-
tion of the Ministry of Health and with the involve-
ment of experts in the field and the Cancer Plan is 
expected to be adopted in 2020.
CONCLUSION
Cancer is a complex problem, both from clin-
ical and public health perspective. The epidemio-
logical data for Croatia are worrying, with high 
mortality and low survival indicating a major im-
pact on the health of people living in Croatia. The 
gap behind more developed countries is not being 
reduced, and it represents a major challenge for 
Croatian society in the following period. The pri-
mary prevention efforts need to be coordinated by 
a multi-sectoral group of stakeholders, not only 
those related to health care field. In the treatment 
of an individual patient, it is often necessary to ap-
ply different types of therapy with the collabora-
tion of a multidisciplinary team of specialists. The 
population-level approach for this major issue 
from the health care perspective should be the 
same (24): only by involving professionals of dif-
ferent profiles, from clinicians, basic science, gen-
eral practitioners, public health and epidemiolo-
gy, management at the Ministry of Health and the 
Croatian Health Insurance Institute and of course 
patients’ associations, a positive breakthrough in 
these cancer statistics and a longer and healthier 
life for citizens of this country can be achieved. 
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